FDA Signs Off on aTyr’s Revised Phase 3 Plan in Pulmonary Sarcoidosis

After EFZO-FIT missed, aTyr has FDA alignment on a narrower Phase 3 using FVC. Cash funds operations into 2028, but not the new trial.